Cellectricon Launches World's First System for High Throughput RNAi Screening

GOTHENBERG, Sweden, March 27 /PRNewswire/ -- Cellectricon, a leading provider of screening solutions for drug discovery, today announced the launch of the new Cellaxess(R)HT System. The world's first fully automated high throughput transfection system enables reagent-free delivery of genetic material to a wide range of biologically relevant cell types. The system will be introduced at the SBS 14th Annual Conference and Meeting in St. Louis, MO, USA, April 6-10.

Cellectricon has developed Cellaxess(R)HT in close collaboration with leading research groups to meet the increasing demand for a technology capable of genome-wide RNAi screening.

"We are very pleased to meet the industry's demand by bringing this state-of-the-art system to the market." says Dr. Mattias Karlsson, CEO of Cellectricon. "Cellaxess(R)HT will revolutionize target discovery by opening the door to using more biologically relevant cell types in genome-wide RNAi screening."

About the Cellaxess(R)HT system

Cellaxess(R)HT addresses the critical need for high throughput delivery of siRNA and cDNA to hard to transfect cells in several cell-based screening assays. Cellaxess(R)HT is the only fully automated system on the market allowing for high throughput transfection of cells in culture directly in 384-well microplates. The system enables reagent-free delivery to a wide range of biologically relevant cell types with excellent efficiency and viability at a throughput of 50 000 wells per day.

About Cellectricon

Cellectricon is a key innovator and solutions provider of advanced cell-based screening products to accelerate biotechnology and drug discovery. The company's successfully launched products are aimed at critical bottlenecks in the drug discovery process and have been adopted by top-reference customers including the top ten pharmaceutical companies. To date, the company has launched two products with exceptional market acceptance targeting the ion channel screening and transfection markets. The company utilizes state-of-the-art interfaces to biological systems by employing novel microfabrication technologies and smart engineering solutions. This enables completely new types of assays and devices with superior performance characteristics and robustness.

SOURCE Cellectricon AB

Suggested Articles

Almirall and Iktos will use the latter's AI technology to design new compounds that tick multiple drug criteria boxes.

Pfizer’s 2017 spinout company SpringWorks has lost president and founder Lara Sullivan, M.D., who has moved over to Pyxis Oncology as its new chief.

In this week's EuroBiotech Report, Sanofi inks $2.5B Synthorx takeover and posts sutimlimab data, Roche shares bispecific results and more.